R&D channel feed

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

6 years ago

A JP Mor­gan promise, a last-minute bid and the coro­n­avirus stock mar­ket — how Gilead’s Daniel O’Day nabbed Forty Sev­en

6 years ago
Deals

With WuXi and Al­ny­lam in tow, Vir en­lists NIH as it tests var­i­ous tools to fight the coro­n­avirus scourge

6 years ago
Coronavirus

An­a­lysts start to sort out which bio­phar­ma com­pa­nies’ R&D plans are most threat­ened by a pan­dem­ic

6 years ago
Coronavirus

In search of a Ku­ur: Cell Med­ica re­brands and re­groups, tak­ing a new name, a new CEO and new mon­ey

6 years ago

The glob­al top 50 bio­phar­ma com­pa­nies — End­points News style

6 years ago

Intar­ci­a's speed bump at the FDA turns in­to a road­block, as reg­u­la­tors once again turn thumbs down on di­a­betes drug/de­vice

6 years ago
Pharma

To arm the im­mune sys­tem for sus­tained at­tack against HIV, NIH sci­en­tists take to vi­ral vec­tors

6 years ago
Cell/Gene Tx

Bris­tol My­ers backs a Eu­ro­pean VC's record-set­ting biotech ven­ture fund, which tops out at $600M

6 years ago
Pharma

An­oth­er myo­statin pro­gram com­busts, but Ac­celeron has plen­ty in the pipeline

6 years ago

Unum racks up yet an­oth­er FDA hold as it twists its way through a re­struc­tur­ing, look­ing for a fresh start with a pre­clin­i­cal drug

6 years ago

Bris­tol My­ers flunks front­line mul­ti­ple myelo­ma tri­al, turn­ing at­ten­tion to cell ther­a­py

6 years ago
Cell/Gene Tx

With pos­i­tive key tri­al, Kala Phar­ma's dry eye drug Ey­su­vis em­u­lates ap­proval path set by Xi­idra

6 years ago

Se­ri­ous side ef­fects side­line small Roche study of an ex­per­i­men­tal Hunt­ing­ton’s drug from Io­n­is

6 years ago

Lob­by­ing cam­paign killed pro­pos­al to set price lim­its on fu­ture coro­n­avirus drugs, vac­cines — re­port

6 years ago
Coronavirus

As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

6 years ago
Pharma

Macro­Gen­ics los­es CMO Jon Wig­gin­ton as com­mer­cial­iza­tion looms

6 years ago
People

How do de­pressed rats re­spond to psy­che­delics? New da­ta of­fer in­sight in­to the hu­man ex­pe­ri­ence

6 years ago

Tack­ling in­her­it­ed blind­ness, Ed­i­tas and Al­ler­gan use CRISPR for the first time in the hu­man body

6 years ago

Ab­b­Vie and Al­ler­gan fi­nal­ly set (rough) date for wed­ding as one par­ent agrees to the match

6 years ago
Deals

New study sug­gests it costs $1.3B in R&D in­vest­ment to bring a drug to mar­ket. How did it get there?

6 years ago

Amu­nix grabs $73M from Fra­zier, Omega to fu­el shift to T cell en­gagers

6 years ago

Add Take­da and Al­ny­lam to the menu of glob­al drug­mak­ers look­ing to stymie the coro­n­avirus epi­dem­ic

6 years ago
Pharma
Coronavirus

Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance

6 years ago
First page Previous page 211212213214215216217 Next page Last page
A service from the Financial Times